Inhibition of invasion and migration of salivary gland adenocarcinoma cells by 5′-nitro-indirubinoxime (5′-NIO)

Head and Neck

Volumn 32, Issue 5, 2010, Pages 619-625

  Yoon, Ji Hye ^a   Kim, Soo A ^b   Kim, Jae Il ^c   Park, Jong Hwan ^a   Ahn, Sang Gun ^a   Yoon, Jung Hoon ^a  

^a Chosun University   (South Korea)

^b Dongguk University   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

1 integrin; 5 nitro indirubinoxime (5 NIO); Invasion; Migration; Salivary gland cancer

Indexed keywords

5' NITROINDIRUBINOXIME; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; GELATINASE A; GELATINASE B; INDIRUBIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; ANTIGENS, CD29; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; OXIMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVARY GLAND NEOPLASMS;

EID: 77951582520     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21230     Document Type: Article

References (46)

1. Etges A, Nunes FD, Ribeiro KC, Araujo VC. Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours. Oral Oncol 2004;40:326-331. (Pubitemid 38121571)
2. Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 2007;43:729-734. (Pubitemid 47259451)
3. Prenen H, Kimpe M, Nuyts S. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. Curr Opin Oncol 2008;20:270-274. (Pubitemid 351507546)
4. Barnes L, Everson JW, Reichart, P. World Health Organization classification of tumours. Lyon, France: IARC Press; 2005.
5. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996;27:561-566. (Pubitemid 26187279)
6. Sugano S, Mukai K, Tsuda H, et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 1992;102:923-927.
7. Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M, Viale G. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). J Pathol 1997;181:323-329. (Pubitemid 27156847)
8. Nagao T, Sugano I, Ishida Y, et al. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. Cancer 1998;82:439-447. (Pubitemid 28112980)
9. Horn-Ross PL, Morrow M, Ljung BM. Diet and the risk of salivary gland cancer. Am J Epidemiol 1997;146:171-176. (Pubitemid 27329201)
10. Spiro RH. Management of malignant tumors of the salivary glands. Oncology (Williston Park) 1998;12:671-680,683.
11. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006;42:759-769.
12. Zhang ZN, Liu EK, Zheng TL, Li DG. Treatment of chronic myelocytic leukemia (CML) by traditional Chinese medicine and Western medicine alternately. J Tradit Chin Med 1985;5:246-248.
13. Kim SA, Kim YC, Kim SW, et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res 2007;13:253-259. (Pubitemid 46121877)
14. Lee JW, Moon MJ, Min HY, et al. Induction of apoptosis by a novel indirubin-5-nitro-3′-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg Med Chem Lett 2005;15:3948-13452
15. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004;130:627-635. (Pubitemid 39506375)
16. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999;1:60-67. (Pubitemid 129495012)
17. Kim SA, Kim SW, Chang S, Yoon JH, Ahn SG. 5′-Nitroindirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett 2009;274:72-77.
18. Marko D, Schatzle S, Friedel A, et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001;84:283-289. (Pubitemid 32113458)
19. Merz KH, Schwahn S, Hippe F, Muhlbeyer S, Jakobs S, Eisenbrand G. Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases. Int J Clin Pharmacol Ther 2004;42:656-658.
20. Shrestha P, Sumitomo S, Lee CH, et al. Tenascin: growth and adhesion modulation-extracellular matrix degrading function: an in vitro study. Eur J Cancer B Oral Oncol 1996;32B:106-113. (Pubitemid 26153213)
21. Lin TH, Kuo HC, Chou FP, Lu FJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer 2008;8:58.
22. Hidalgo K, Rojas IG, Penissi AB, Rudolph MI. TNFalpha increases in vitro migration of human HPV18-positive SW756 cervical carcinoma cells. Biocell 2005;29:303-311. (Pubitemid 43267031)
23. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
24. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-433. (Pubitemid 37328846)
25. Kameswaran TR, Ramanibai R. Indirubin-3-monooxime induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells. Biomed Pharmacother 2009;63:146-154.
26. Libnow S, Methling K, Hein M, et al. Synthesis of indirubin-N′- glycosides and their anti-proliferative activity against human cancer cell lines. Bioorg Med Chem 2008;16:5570-5583. (Pubitemid 351694473)
27. Sethi G, Ahn KS, Sandur SK, Lin X, Chaturvedi MM, Aggarwal BB. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem 2006;281:23425-32345. (Pubitemid 44274117)
28. Shi J, Shen HM. Critical role of Bid and Bax in indirubin-3′- monoxime-induced apoptosis in human cancer cells. Biochem Pharmacol 2008;75:1729-1742.
29. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
30. Irie HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-1034.
31. Sankar S, Mahooti-Brooks N, Hu G, Madri JA. Modulation of cell spreading and migration by pp125FAK phosphorylation. Am J Pathol 1995;147:601-608.
32. Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src. J Biol Chem 1997;272:13189-13195.
33. Somanath PR, Kandel ES, Hay N, Byzova TV. Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly. J Biol Chem 2007;282:22964-22976.
34. Sonoda Y, Watanabe S, Matsumoto Y, Aizu-Yokota E, Kasahara T. FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J Biol Chem 1999;274:10566-10570.
35. Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 2005;156:141-150.
36. Lee SJ, Park SS, Lee US, Kim WJ, Moon SK. Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol 2008;8:1821-1826.
37. Fukasawa M, Matsushita A, Korc M. Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther 2007;6:1173-1180. (Pubitemid 351590368)
38. Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1996;1287:67-71.
39. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996;8:724-730.
40. Morini M, Mottolese M, Ferrari N, et al. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000;87:336-342.
41. Lee KJ, Hwang SJ, Choi JH, Jeong HG. Saponins derived from the roots of Platycodon grandiflorum inhibit HT-1080 cell invasion and MMPs activities: regulation of NF-kappaB activation via ROS signal pathway. Cancer Lett 2008;268:233-243.
42. Pasco S, Brassart B, Ramont L, Maquart FX, Monboisse JC. Control of melanoma cell invasion by type IV collagen. Cancer Detect Prev 2005;29:260-266.
43. Hung SH, Shen KH, Wu CH, Liu CL, Shih YW. Alpha-mangostin suppresses PC-3 human prostate carcinoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen expression through the JNK signaling pathway. J Agric Food Chem 2009;57:1291-1298.
44. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23.
45. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998;2:466-471.
46. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-792.